Résultats de la recherche

19 résultats trouvés pour ""

  • Home | hPG80 - A major target against Cancer | ECS Progastrin

    Last updated: August 3, 2020 HOWEVER The real battle against cancer is fought by physicians and patients! Our mission is simply to provide healthcare professionals with innovative tools that are the most reliable and effective possible. The hPG 80 blood biomarker has now been shown to be both a major weak point of cancer and a fundamental target to providing physicians with multiple solutions, now and in the future : * In cancer, hPG 80 is overexpressed in the tumor and detectable in the patient’s blood [1] . 16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date [1] . ​ Cancer stem cells express elevated levels of hPG 80 (circulating progastrin) [2][3] . Secretion of hPG 80 maintain tumor-initiating and self-renewal capabilities of cancer stem cells [3] . hPG 80 is released from the tumor and becomes detectable in the blood across all stages [3][4] . Plasma hPG 80 is elevated in a wide range of cancer patients [5] hPG 80 is produced by all cancer cells, but in quantities 100 to 1000 times higher by cancer stem cells [2] , making hPG 80 the only blood biomarker that gives information on tumor activity. BIBLIOGRAPHY [1]. You et al, EBioMedicine, 2020 Jan;51:102574 [2]. Giraud et al, Cancer Res, 2016;76(12):3618-28 [3]. Siddheshwar et al, Gut, 2001 Jan; 48(1): 47–52 [4]. Prieur et al, Clin Cancer Res. 2017;23(17):5267–5280 [5]. Konieczkowski et al, Cancer Cell, 2018 May 14;33(5):801-815 KEY FACTS CURRENT AND PROSPECTIVE CLINICAL APPLICATIONS CURRENT FOLLOW UP hPG 80 measurement, and its trend, from simple blood samples, can help Physicians in the follow-up of patients, providing them with additional meaningful information on: treatment efficacy , risk of minimal residual disease, risk of relapse. CURRENT DIAGNOSIS The presence or absence of hPG 80 in blood can also provide Physicians with an additional indicator of vigilance for earlier diagnosis , especially for at-risk populations and for cancers for which no biomarker exists . PROSPECTIVE OTHER USES In addition, other potential uses for hPG 80 are being investigated and will be available to physicians in a few years: hPG 80 neutralization has shown that it can lead to a new clinical approach to tumor reversion therapy that causes cancer cells to return to “normal”, hPG 80 can provide a major breakthrough in tumor localization by PET Scan imaging, Finally, the robustness of its detection in blood makes it possible to envisage in the short term the production of a hPG 80 rapid test providing physicians and health authorities with a new affordable and very minimally invasive tool that could help them in their early detection strategies. NOW AVAILABLE TO PHYSICIANS A NEW TOOL : The blood test for detection and measurement of the target hPG80 Learn more... AVAILABLE ONLY ON MEDICAL PRESCRIPTION Contact Us Medical Doctor / Docteur en médecine Medical Professor / Professeur en médecine Mr. / M Ms. / Mme I fully read and agree to the privacy policy. / J'ai lu et j'accepte les clauses de confidentialité. Send / Envoyer Thank you for your message / Merci pour votre message

  • Press Corner | hPG80 | Cancer | DxPG80 | ECS Progastrin

    Press Corner PRESS ENQUIRIES ➜ Contact us via e-mail Subscription Welcome to our press mailing list OUR HISTORY ➜ From the lab to the patient Last updated: August 3, 2020 PHOTOS & LOGOS PHOTOS & LOGOS VIDEOS VIDEOS PRESS RELEASES Posts Are Coming Soon Stay tuned... PRESS RELEASES PRESS RELEASES VIDEOS VIDEOS PHOTOS & LOGOS Icone Logo format: Illustrator picture Logo_Puce 2020.ai PHOTOS & LOGOS PHOTOS & LOGOS VIDEOS PRESS RELEASES PRESS RELEASES Dominique Joubert Presentation Video length : 2:30' French (English subtitle) Royalty-free video on demand ​ From the lab to the patient Performing a scientific demonstration and bringing it to the patient is the dream of every scientist that Dominique Joubert is living. The scientific demonstration in question here is a major precision: to be able to detect cancer and to reverse the tumour process, in other words, to "bring back to cells that were cancerous" normal . Our Montpellier laboratory Video length : 1:01' Video without audio royalty-free video on demand ​ ​ Lyon CHU laboratory Video length : 3:06' Video without audio royalty-free video on demand ​ ​ It's time to control cancer Contact us Send Your message has been sent.

  • hPG80 & Cancer | hPG80 for Hepatocellular Carcinoma | ECS Progastrin

    Contract signed with: CHU Montpellier, France Principal investigator: Eric Assenat hPG 80 is a biomarker for monitoring of treatment response and recurrence in Hepatocellular Carcinoma patients Last updated: August 3, 2020 1 Scientific context : Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth leading cause of cancer death . More than 800,000 new HCC cases are diagnosed annually, and more than 800,000 patients die each year . It develops in a cirrhotic liver in about 90% of cases, appearing rarely on healthy livers or with non-cirrhotic chronic liver diseases . (1) (2) (3) Curative treatments such as hepatic resection, liver transplantation and percutaneous ablation are offered in only 30-40% of patients . Therefore, the majority of patients receive palliative care to increase survival. Treatments include transarterial chemoembolization (TACE), transarterial radioembolization (TARE), systemic therapies with chemo or molecular targeted therapies (sorafenib and regorafenib). (4) Currently, serum alpha-fetoprotein (AFP) is the most widely used marker for diagnosing HCC. However, with a cut-off value of 20 ng/mL, the sensitivity of AFP is only 60%, and therefore AFP alone should not be used for screening . Indeed, AFP levels are not elevated in 80% of patients with small tumors . On the other hand, AFP levels can be increased in patients with chronic liver disease (e.g. hepatitis) . Furthermore, the use of AFP in HCC surveillance remains controversial . (5) (6, 7) (8) (9) Progastrin is an intracellular protein that is, or not, maturated into gastrin. When progastrin is maturated into gastrin, it is released from the cells. When gastrin is produced by the G cells of the stomach antrum, it plays its role to control acidic secretions during digestion. If progastrin is not maturated into gastrin, it is released from the cells as such and named hPG80. This only happens in tumor cells: progastrin becomes a circulating protein, hPG80, which can be detected in the blood of cancer patients. The expression of the progastrin gene, GAST, is frequently increased, at early stages of tumor development, especially in colorectal cancer (but also in other cancers such as stomach, pancreatic, lung or ovarian cancer) . Several signaling pathways have been involved in this process. In particular, activation of the Wnt/β-catenin pathway leads to overexpression of GASTand is involved in hepatic regeneration and in the transcriptional control of the metabolic compartmentalization of hepatic functions. Three types of liver tumors are associated with an aberrant activation of the Wnt/β-catenin pathway: hepatoblastoma, HCC and hepatocellular adenoma. In this context, hPG80 dosage might be used for early diagnosis of HCC. (10) 2 hPG80, a new blood based biomarker Non Pathologic Condition Progastrin is not found in the blood of healthy people. When progastrin is maturated into gastrin, it is released from the cells. ​ When gastrin is produced by the G cells of the stomach antrum, it plays its role to control acidic secretions during digestion. Objective Pathologic Condition hPG 80 is detected in the blood of cancer patients. When progastrin is not maturated into gastrin, it is released from the cells as such and named hPG 80 . ​ This only happens in tumor cells, whatever the tumor cell: progastrin becomes a circulating protein, hPG 80 , which can be detected in the blood of cancer patients. 3 Objectives: ​ Evaluate the value of hPG80 blood levels in monitoring of treatment response and recurrence in hepatocellular carcinoma patients. Examine whether hPG80 outperforms AFP to diagnose and monitor the disease. Analyze whether hPG80 levels were influenced by inflammation, assessed by CRP concentration. ​ 4 Patients: The hepatocellular carcinoma (HCC) cohort (PRO-HCC) came from the CHU (Centre Hospitalier Universitaire) Montpellier biobank (BB-0033-00031; the “Liverpool” collection; DC 2014-2328; AC 2014-2335; Montpellier, France). PRO-HCC is a cohort of 84 patients with HCC, managed with local or systemic treatments (nevaxar, tepotinib, regorafenib, nivolumab, anti-FGR or carbozantinib), including molecular targeted agents (“Liverpool” collection). 5 Results: 5. 1 hPG80 is detected at all stages Figure 2. hPG80 kinetics in patients receiving cancer treatments in PRO-HCC cohort at progression vs remission. (A) All patients (n=84): Changes in median hPG80 levels from baseline (11.54 pM (IQR: 3.25 pM-28.28 pM)), to progression (15.71 pM (IQR:6.33-37.26 pM)), or remission (1.99 pM (IQR: 0.00-8.30 pM)). (B) Patients with normal alfa-fetoprotein (AFP) value (n=32): Changes in median hPG80 levels from baseline (14.16 pM (IQR: 7.56 pM-42.34 pM)), to progression (18.33 pM (IQR: 11.71 pM-53.70 pM)), or remission (1.47 pM (IQR: 0.21 pM-4.44 pM)). Figure 1. ​ hPG80 levels at different disease stages (focal, n=23; locally advanced, n=42; metastatic, n=19) and at disease remission after treatment (n=32). In order to simplify the reading of the graph, only statistically significant differences were shown on the graph. All the other comparisons were tested and none of them were significant. The study cohort comprises 84 patients with HCC at different disease stages: focal (n=23); locally advanced (n=42), metastatic (n=19) and at disease remission after treatment (n=32). ​ As shown in Figure 1 and 2A, hPG80 was detected in the blood of HCC patients whatever the stages. Patients in remission after disease management had lower hPG80 levels compared to those with active cancers. 5. 2 Comparison between hPG80 and AFP Figure 3. hPG80 and AFP levels in all HCC patients. 5. 3 Diagnostic performance of hPG80 in HCC patients Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic discriminative accuracy of hPG80 levels in HCC patients compared to healthy blood donors control group. As shown on Figure 3, hPG80 levels displayed high predictive significance, with an area under the curve (AUC) value of 0.85 (95% CI: 0.79-0.91; p< 0.0001) when compared to healthy blood donors. Figure 4. Diagnostic discriminative accuracy of hPG80 in patients with HCC compared to 137 healthy blood donors (age 18-25 years old) using Receiver Operating Characteristics (ROC) curve analysis. 5. 4 hPG80 and AFP kinetics in HCC patients receiving cancer treatment Individual concentration versus time curves of hPG80 evolved consistently with disease activity and AFP kinetics in most patients. This is illustrated by seven typical patients profiles (Figure 5, 6 and 7). Figure 5. ​ hPG80 kinetics in patients receiving cancer treatments in PRO-HCC cohort. Longitudinal kinetics of alfa-fetoprotein (AFP) and hPG80 in 4 typical HCC patients during treatments. Figure 6. hPG80 kinetics in patients receiving cancer treatments in PRO-HCC cohort. ​ Illustrative hPG80 longitudinal changes around and during disease management (baseline; remission; progression), with associated imaging obtained at the same times (multifocal liver involvement at baseline; remission after treatment with nivolumab; new liver lesions on ultrasound at progression) in a typical patient. Figure 7. ​ hPG80 kinetics in patients receiving cancer treatments in PRO-HCC cohort with imaging. Longitudinal kinetics of alfa-fetoprotein (AFP) and hPG80 during treatments in 2 typical HCC patients, with consistent imaging findings. The AFP of the patient in panel A was not informative due to low concentration below the upper limit-of-normal 20 ng/ml cut-off. 5. 5 hPG80 and AFP kinetics in HCC patients receiving cancer treatment 1 Scientific context Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth leading cause of cancer death . More than 800,000 new HCC cases are diagnosed annually, and more than 800,000 patients die each year . It develops in a cirrhotic liver in about 90% of cases, appearing rarely on healthy livers or with non-cirrhotic chronic liver diseases . (1) (2) (3) Curative treatments such as hepatic resection, liver transplantation and percutaneous ablation are offered in only 30-40% of patients . Therefore, the majority of patients receive palliative care to increase survival. Treatments include transarterial chemoembolization (TACE), transarterial radioembolization (TARE), systemic therapies with chemo or molecular targeted therapies (sorafenib and regorafenib). (4) Currently, serum alpha-fetoprotein (AFP) is the most widely used marker for diagnosing HCC. However, with a cut-off value of 20 ng/mL, the sensitivity of AFP is only 60%, and therefore AFP alone should not be used for screening . Indeed, AFP levels are not elevated in 80% of patients with small tumors . On the other hand, AFP levels can be increased in patients with chronic liver disease (e.g. hepatitis) . Furthermore, the use of AFP in HCC surveillance remains controversial . (5) (6, 7) (8) (9) Progastrin is an intracellular protein that is, or not, maturated into gastrin. When progastrin is maturated into gastrin, it is released from the cells. When gastrin is produced by the G cells of the stomach antrum, it plays its role to control acidic secretions during digestion. If progastrin is not maturated into gastrin, it is released from the cells as such and named hPG 80 . This only happens in tumor cells: progastrin becomes a circulating protein, hPG 80 , which can be detected in the blood of cancer patients. The expression of the progastrin gene, , is frequently increased, at early stages of tumor development, especially in colorectal cancer (but also in other cancers such as stomach, pancreatic, lung or ovarian cancer) . Several signaling pathways have been involved in this process. In particular, activation of the Wnt/β-catenin pathway leads to overexpression of and is involved in hepatic regeneration and in the transcriptional control of the metabolic compartmentalization of hepatic functions. Three types of liver tumors are associated with an aberrant activation of the Wnt/β-catenin pathway: hepatoblastoma, HCC and hepatocellular adenoma. In this context, hPG GAST (10) GAST 80 dosage might be used for early diagnosis of HCC. 2 hPG80, a new blood based biomarker Non Pathologic Condition hPG 80 is not found in the blood of healthy people. When progastrin is maturated into gastrin, it is released from the cells. ​ When gastrin is produced by the G cells of the stomach antrum, it plays its role to control acidic secretions during digestion. Objective Pathologic Condition When progastrin is not maturated into gastrin, it is released from the cells as such and named hPG 80 . ​ This only happens in tumor cells, whatever the tumor cell: progastrin becomes a circulating protein, hPG 80 , which can be detected in the blood of cancer patients. hPG 80 is detected in the blood of cancer patients. 3 Objectives ​ Evaluate the value of hPG80 blood levels in monitoring of treatment response and recurrence in hepatocellular carcinoma patients. Examine whether hPG80 outperforms AFP to diagnose and monitor the disease. Analyze whether hPG80 levels were influenced by inflammation, assessed by CRP concentration. ​ 4 Patients The hepatocellular carcinoma (HCC) cohort (PRO-HCC) came from the CHU (Centre Hospitalier Universitaire) Montpellier biobank (BB-0033-00031; the “Liverpool” collection; DC 2014-2328; AC 2014-2335; Montpellier, France). PRO-HCC is a cohort of 84 patients with HCC, managed with local or systemic treatments (nevaxar, tepotinib, regorafenib, nivolumab, anti-FGR or carbozantinib), including molecular targeted agents (“Liverpool” collection). 5 Result 5. 1 hPG80 is detected at all stages Figure 2. hPG80 kinetics in patients receiving cancer treatments in PRO-HCC cohort at progression vs remission. (A) All patients (n=84): Changes in median hPG80 levels from baseline (11.54 pM (IQR: 3.25 pM-28.28 pM)), to progression (15.71 pM (IQR:6.33-37.26 pM)), or remission (1.99 pM (IQR: 0.00-8.30 pM)). (B) Patients with normal alfa-fetoprotein (AFP) value (n=32): Changes in median hPG80 levels from baseline (14.16 pM (IQR: 7.56 pM-42.34 pM)), to progression (18.33 pM (IQR: 11.71 pM-53.70 pM)), or remission (1.47 pM (IQR: 0.21 pM-4.44 pM)). Figure 1. ​ hPG80 levels at different disease stages (focal, n=23; locally advanced, n=42; metastatic, n=19) and at disease remission after treatment (n=32). In order to simplify the reading of the graph, only statistically significant differences were shown on the graph. All the other comparisons were tested and none of them were significant. The study cohort comprises 84 patients with HCC at different disease stages: focal (n=23); locally advanced (n=42), metastatic (n=19) and at disease remission after treatment (n=32). ​ As shown in Figure 1 and 2A, hPG80 was detected in the blood of HCC patients whatever the stages. Patients in remission after disease management had lower hPG80 levels compared to those with active cancers. 5. 2 Comparison between hPG80 and AFP Figure 3. hPG80 and AFP levels in all HCC patients. 5. 3 Diagnostic performance of hPG80 in HCC patients Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic discriminative accuracy of hPG80 levels in HCC patients compared to healthy blood donors control group. As shown on Figure 3, hPG80 levels displayed high predictive significance, with an area under the curve (AUC) value of 0.85 (95% CI: 0.79-0.91; p< 0.0001) when compared to healthy blood donors. Figure 4. Diagnostic discriminative accuracy of hPG80 in patients with HCC compared to 137 healthy blood donors (age 18-25 years old) using Receiver Operating Characteristics (ROC) curve analysis. 5. 4 hPG80 and AFP kinetics in HCC patients receiving cancer treatment Individual concentration versus time curves of hPG80 evolved consistently with disease activity and AFP kinetics in most patients. This is illustrated by seven typical patients profiles (Figure 5, 6 and 7). Figure 5. ​ hPG80 kinetics in patients receiving cancer treatments in PRO-HCC cohort. Longitudinal kinetics of alfa-fetoprotein (AFP) and hPG80 in 4 typical HCC patients during treatments. Figure 6. hPG80 kinetics in patients receiving cancer treatments in PRO-HCC cohort. ​ Illustrative hPG80 longitudinal changes around and during disease management (baseline; remission; progression), with associated imaging obtained at the same times (multifocal liver involvement at baseline; remission after treatment with nivolumab; new liver lesions on ultrasound at progression) in a typical patient. Figure 7. ​ hPG80 kinetics in patients receiving cancer treatments in PRO-HCC cohort with imaging. Longitudinal kinetics of alfa-fetoprotein (AFP) and hPG80 during treatments in 2 typical HCC patients, with consistent imaging findings. The AFP of the patient in panel A was not informative due to low concentration below the upper limit-of-normal 20 ng/ml cut-off. 5. 5 hPG80 and AFP kinetics in HCC patients receiving cancer treatment Figure 8. Impact of CRP on hPG80 levels in patients with cancer. Baseline hPG80 concentrations versus C reactive protein levels (CRP) in the PRO-HCC cohort. As shown on Figure 8, we found no link between hPG80 and inflammation status, assessed by CRP concentration, suggesting that, if any, impact of inflammation is probably limited. 6 Conclusion hPG80 is detected in the blood of HCC patients whatever the stage and remission is associated to lower levels of hPG80. ​ Upon treatment, hG80 follows disease evolution and witnesses treatment efficacy and recurrence. ​ Therefore, these data support the potential use of hPG80 as a biomarker for HCC patient follow-up. ​ In addition, we showed that hPG80 is a better biomarker than AFP to detect HCC. 7 Bibliography Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR.2019. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589-604. 1. ​ Global Burden of Disease Liver Cancer C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY, Cowie B, Dandona L, Dandona R, Dey S, Dicker D, Phuc H, Ekwueme DU, Zaki MS, Fischer F, Furst T, Hancock J, Hay SI, Hotez P, Jee SH, Kasaeian A, Khader Y, Khang YH, Kumar A, Kutz M, Larson H, Lopez A, Lunevicius R, Malekzadeh R, McAlinden C, Meier T, Mendoza W, Mokdad A, Moradi-Lakeh M, Nagel G, Nguyen Q, Nguyen G, et al.2017. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. 3:1683-1691. 2. ​ Renedo F DlRJ, Calleja JL.2008. Carcinoma hepatocelular. Medicine 10:770–6. 3. ​ Bruix J, Llovet JM.2002. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519-24. 4. ​ Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M.2001. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34:570-5. 5. ​ Zhang XF, Qi X, Meng B, Liu C, Yu L, Wang B, Lv Y.2010. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems. Eur J Surg Oncol 36:718-24. 6. ​ Agopian VG, Harlander-Locke MP, Markovic D, Zarrinpar A, Kaldas FM, Cheng EY, Yersiz H, Farmer DG, Hiatt JR, Busuttil RW.2017. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce alpha-Fetoprotein. JAMA Surg 152:55-64. 7. ​ Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T, Kitabatake S, Kuzuya T, Nonogaki K, Kasugai T, Shimizu J.2004. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. Cancer 100:2415-21. 8. ​ Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W.2016. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 22:262-74. 9. ​ You B, Mercier F, Assenat E, et al : The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine 51:102574, 2020 10.

  • hPG80 | Performances | ECS Progastrin

    hPG 80 Performances A performing biomarker. Present at all stages and for Multiple Cancer Types. Last updated: August 3, 2020 1 Healthy Blood Donors vs All Combined Cancers Significant increase in hPG 80 levels in all cancer patients (N= 1267, Median hPG 80 = 4.77 pM) compared to healthy blood donors (N=557 for 18-70 yo, Median hPG 80 = 1.05 pM and N=137 for 18-25 yo, Median hPG 80 = 0.2 pM). You B, Mercier F, Assenat E, et al : The oncogenic and druggable hPG80 is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine 51:102574, 2020 2 Diagnostic des performances de hPG 80 par types de tumeurs Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037. 3 Performances of hPG 80 vs Existing Tumor Markers BREAST CANCER Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer – A retrospective analysis of kinetics on 743 breast cancer patients. Stieber P et al., Clin Chim Acta., 2015. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard,Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037. N=53 patients. N=9 patients, work ongoing. COLORECTAL CANCER CEA Monitoring in Colorectal Cancer. Fakih MG, Padmanabhan A., Oncology (Williston Park), 2006. Cutoff at 5 ng/mL. Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening. Gies A et al., Gastroenterology, 2018. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037. N = 98 patients. N = 192 patients. OVARIAN CANCER Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Chen F et al., Cancer Manag Res, 2018. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037. N = 27 patients. N = 181 patients. PROSTATE CANCER A review on the clinical Utility of PSA in Cancer Prostate. Adhyam M, Gupta AK; Indian J Surg Oncol, 2012. PSA cutoff at 4 ng/mL. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, VéroniqueSaywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037. N = 93 patients. N = 444 patients. HEPATOCELLULAR CARCINOMA Serum tumor markers for detection of hepatocellular carcinoma. Zhou L et al., World J Gastroenterol., 2006. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037. N = 27 patients. N = 65 patients. hPG 80 has a better sensitivity to detect HCC than AFP. AFP was above 20ng/ml in 54.3% of the samples while hPG 80 (circulating progastrin) was detected in 80.2% (threshold = 1pM). ​ Progastrin a new biomarker for hepatocellular cancer patient follow-up. Alexandre Prieur, Marie Dupuy, Pierre Liaud, Dominique Joubert and Eric Assenat. AACR 2019 - Poster #2222. 4 hPG80 for the monitoring of Minimal Residual Disease and Response to Treatment PERITONEAL CARCINOMATOSIS A cohort of patients with peritoneal involvements from gastrointestinal cancers, treated with peri-operative chemotherapy regimens and cytoreductive surgery (Lyon, France, NCT02823860). Global analysis. High levels of before surgery. Decrease of 8h to 24h after surgery (From 3.08 pM to 1.57 pM; p=0.035). hPG 80 hPG 80 Individual analysis. 74.2% of the patients had a decrease of at least 25% of levels after surgery. hPG 80 Sustained elevations in concentrations after surgery could be suggestive of the presence of residual disease. hPG 80 You B, Mercier F, Assenat E, et al : The oncogenic and druggable hPG 80 is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine 51:102574, 2020 Gilles Freyer, Delphine Maucort-Boulch, Dominique Joubert and Olivier Glehen. ESMO 2018 - Poster # 1953. PROSTATE CANCER Elevated levels in patients with advanced prostate cancer (aPCa)* (healthy blood donors 18 to 40 yo: median = 0.37 pM vs aPCa: median = 4.7 pM, p<0.0001). hPG 80 hPG 80 hPG 80 *aPCa includes metastatic hormone sensitive (mHSPC) and metastatic castration resistant (mCRPC) prostate cancer patients. Overall survival (OS) according to levels evolution during follow-up. Patients with a serial increase of had a worst overall survival compare to the other group (9.3 yo vs 12.4 yo, P = 0.019). hPG 80 hPG 80 Plasma Progastrin Level As A Prognostic Biomarker In Advanced Prostate Cancer. Manish Kohli, Winston Tan, Léa Payen, Carole Langlois-Jacques, Pierre Liaud, Delphine Maucort-Boulch, Dominique Joubert and Alexandre Prieur. AACR 2019 - Poster #2294. KIDNEY CANCER Elevated levels in patients with metastatic renal cell carcinoma (mRCC) (Cohort (healthy blood donors18-25 y/o): median = 0.29 pM vs mRCC = 7.2 pM). hPG 80 hPG 80 hPG 80 We compared levels with the MSKCC prognostic criteria for patient survival. In this score, patients are separated in 3 groups: good, intermediate and poor prognostic. levels were higher within the MSKCC score poor prognostic group (p<0.001) (median 30.39 pM vs 6 pM and 9.34 pM in the good and intermediate group, respectively). hPG 80 hPG 80 assay might be useful for defining subsets of mRCC patients with poor survival who need to be treated aggressively. hPG 80 Prognostic Impact Of Progastrin Levels In Blood Compared To MSKCC Based Clinical Prognosis In Metastatic Renal Cell Cancer Patients. Manish Kohli, Winston Tan, Léa Payen, Carole Langlois-Jacques, Pierre Liaud, Delphine Maucort-Boulch, Dominique Joubert and Alexandre Prieur. AACR 2019 - Poster #2289. 5 hPG 80 for the Monitoring of Relapse (Tumor Activity) MONITORING FOR HEPATOCELLULAR CARCINOMA RECURRENCE Earlier detection of small lesions and the monitoring of recurrence may be improved with hPG80 as a supplemental blood-based biomarker, especially in AFP negative populations where there is limited information. Patients in remission following disease management have lower hPG80 concentrations compared to active cancers. 76% of patients with progressing disease during or after treatment had an increased hPG80 > 25%. Illustrative hPG80 longitudinal changes around and during disease management (baseline; remission; progression), with associated imaging obtained at the same times in a typical patient. Progastrin a new biomarker for hepatocellular cancer patient follow-up. Alexandre Prieur, Marie Dupuy, Pierre Liaud, Dominique Joubert and Eric Assenat. AACR 2019 - Poster # 2222. You B, Mercier F, Assenat E, et al : The oncogenic and druggable hPG80 is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine 51:102574, 2020. MONITORING FOR OVARIAN CANCER RECURRENCE 70% of ovarian cancers are not diagnosed until stage III or IV where survival rates are low (48% after 5 years). As a result, cancer recurrence is high (70-95%) following standard treatment by surgery and combination chemotherapy. hPG80, as a blood-based biomarker used in conjunction with CA125, could improve the early detection of residual disease, treatment efficacy, and/or relapse following treatment. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037. L earn more... about hPG 80 Main Scientific Publications

  • From Progastrin to hPG80 | ECS Progastrin

    From Progastrin to hPG 80 Last updated: August 3, 2020 A clarification was needed regarding the name of progastrin, a protein most of the time associated to its historical function as the gastrin precursor when it is intracellular. When it is extracellular (the case for cancer patients), it is no more a precursor of gastrin, it becomes oncogenic and tumor promoter. We decided to name extracellular progastrin hPG 80 to avoid confusion. ​ ​ 1905>1987: From Gastrin to Progastrin Identification of the intracellular precursor of Gastrin ​ The story of progastrin started with the discovery of gastrin in 1905 when John Sydney Edkins showed the existence of a hormone responsible for gastrin acid secretion. This hormone was called gastric secretin, or gastrin. ​ But it is only in 1987 and 88 that the precursor of gastrin was identified and labelled as gastrin, because of its role as a pro-hormone. It is an 80 amino-acid peptide, processed in the endoplasmic reticulum, with gastrin being the final active product of progastrin maturation. pro ​ In physiology, progastrin is mainly expressed in the stomach, where gastrin is secreted from the G cells of the antrum. The major function of gastrin is to regulate acidic secretion. ​ . Therefore, for years, progastrin was only known as the precursor of gastrin ​ ​ ​ 1990>2020: From the gastrin precursor to the oncogenic tumor promoter Extracellular, "Progastrin" is no longer the precursor of Gastrin, it is an oncogenic protein. ​ In 1990, the first link of progastrin with tumor cells was done. Bardram was the first to hypothesize that “a low degree of processing of progastrin could serve as a predictor of a malignant clinical course at an early stage of the disease” (Bardram, 1990). ​ And this is where the story of progastrin starts, independently of that of gastrin. ​ Progastrin was shown to be poorly processed in colorectal cancer (Ciccotosto, 1995; Finley et al., 1993; Imdahl et al., 1995; Kochman et al., 1992; Nemeth et al., 1993; Singh, 1994; Van Solinge et al., 1993b). And soon after, Singh et al demonstrated that progastrin was secreted from these cells cultured in vitro, opening the door to the analysis of a functional autocrine/ paracrine function of progastrin in tumor cells (Singh, 1994; Van Solinge et al., 1993b). Colorectal cancers are not the only cancer type to express progastrin. Ovarian cancers do it also (van Solinge et al., 1993a) as well as liver tumors that express precursor forms of gastrin, in particular progastrin unlike normal liver (Caplin et al., 1999). Pancreatic tumors also express the gastrin gene, with 91% of the tumors with the unprocessed progastrin product (Caplin, 2002). ​ The evidence showing that progastrin could be detected and quantified in the blood of colorectal cancer patients was demonstrated by Siddheshwar et al as early as 2000 (Siddheshwar et al., 2000), later confirmed by Prieur et al (2017). It was also demonstrated that progastrin had to be released from tumor cells in order to exert its oncogenic functions. ​ The presence of progastrin in the blood of cancer patients was extended to 11 different cancers (You et al, 2020), highlighting the potential that progastrin may have in cancer pathology. ​ ​ ​ Early 2020: From Progastrin to hPG80 The protein is changing its name to put an end to the confusion that gives rise to misconceptions. ​ However, the cancer community does not acknowledge progastrin as a cancer target by itself due to its name, progastrin, which always brings us back to the past, progastrin as the precursor of gastrin. Moreover, this misunderstanding is accentuated by the almost systematic confusion with a totally different peptide that is phonetically identical, the Pro-Gastrin Releasing Peptide (proGRP), which can be found in the scientific literature under several spellings (with or without a hyphen in progastrin or sometimes even under the name pre-progastrin releasing peptide...). Thus to date, more than half of the results concerning Progastrin on search engines concern this peptide and not the 80 amino acid molecule encoded by the gene. GAST ​ ​ This is where the story of the hPG 80 begins. ​ Also, in order to clearly distinguish: intracellular progastrin, the precursor to gastrin, extracellular progastrin (hPG 80 ) which exerts oncogenic functions on tumor cells once released from the tumor cells, pro-gastrin releasing peptide (proGRP), we have been using the name hPG 80 since the beginning of 2020 and the publication You et al. to unambiguously refer to the circulating Progastrin historically mentioned in the scientific literature under the single name Progastrin. ​ “h” means human, “PG” means Progastrin and “ 80 ” corresponds to the number of amino acids of this protein. ​ This is where the story of hPG 80 starts: in order to clearly distinguish between progastrin as the precursor of gastrin and progastrin that exerts oncogenic functions on tumor cells once released from tumor cells, we proposed to rename progastrin once released from tumor cells as hPG 80 . ​ Today, hPG 80 is the circulating progastrin, detected in the blood of patients with multiple cancers and exerting major oncogenic functions, the most relevant being that it is required for cancer stem cells survival. ​ Please note that for greater clarity on this site, we now use the name hPG80, referring to extracellular Progastrin.

  • Download | hPG80 | ECS-Progastrin

    Download Last updated: August 3, 2020 Our job is only to produce and market innovative tools for physicians. They then identify and define the best way to use our tools. For this reason, we invite you to follow to visit the "Physician & Patient Support" page of the 's website, an association of healthcare professionals that collects, enhances and diffuses knowledge about hPG80 and its usefulness in the fight against cancer. this link Progastrin Cancer Control Association ​ Documents presently available : White paper on the link between hPG 80 (circulating Progastrin) and cancer Physicians' booklet Leaflet for doctors to give to their patients General and pathological data sheets

  • DxPG80 | IVD test for hPG80 measurement | ECS progastrin

    ​ DxPG 80 HOW-TO GUIDE (FRANCE) Human circulating Progastrin (hPG80) Immunoassay ​ ​ ​ The DxPG80 Elisa test DxPG80 IVD test how-to guide Prescription​ ​ Last updated: August 3, 2020 Access to this page is restricted to healthcare professionals only The DxPG 80 test is an ELISA (Enzyme-Linked Immunosorbent Assay) for the detection of hPG 80 (circulating human progastrin). The test is intended for professional laboratory use only. ​ Please note that for greater clarity, we use the name hPG 80 , referring to extracellular Progastrin. The test is based on the principle of a sandwich ELISA to measure the concentration of hPG 80 in plasma samples that have been collected in EDTA tubes. Briefly, a capture antibody specific for hPG 80 is immobilised on the 96-well plate. The hPG 80 present in the calibrators and samples added to the wells will bind to the immobilized capture antibody. The test plate includes calibrators which are used to estimate the level of hPG 80 in EDTA plasma samples. The wells are washed and an anti- hPG 80 detection antibody coupled to horseradish peroxidase (HRP) is added, resulting in an antibody-antigen-antibody complex. After a second wash, a substrate solution of 3,3',5,5'-Tetramethylbenzidine (TMB) is added to the wells, producing a blue colour directly proportional to the amount of hPG 80 present in the initial sample. The Stop Solution changes the colour from blue to yellow, and the wells are read at 450 nm with a microplate reader. The assay is technically characterised in manual mode by a limit of detection (LOD, 1 pM) and a limit of quantification (LOQ, 3.3 pM). The LOD detects the presence of hPG 80 and the LOQ gives the concentration at which the assay is quantitative. ​ Table 1 : Comparative description of hPG 80 in Controls (healthy blood donors 18-40 years old at low risk of cancer) and Cancer patients (16 cancers tested, all combined)[1]. Reference range are given for a 2.5 (low range) and 97.5 (high range) percentile. IQR: Inter-Quartil Range, 25-75%. SE: Standard Error. BIBLIOGRAPHY [1]. You et al, EBioMedicine, 2020 Jan;51:102574 From the blood test to reporting the result to the physician:

  • hPG80 | Quick Facts | ECS Progastrin

    What is hPG 80 ? hPG 80 in Cancer Evolution Involvement of the Wnt pathway in tumorigenesis hPG 80, the biomarker of tumoral activity ​ Learn more about performances of hPG 80 hPG 80 A New Blood Biomarker to Help Monitoring Tumor Activity for Multiple Cancers Last updated: August 3, 2020 1 What is hPG80? Progastrin is an intracellular protein that is, or not, maturated into gastrin. Non Pathologic Condition Progastrin is not found in the blood of healthy people. When progastrin is maturated into gastrin, it is released from the cells. ​ When gastrin is produced by the G cells of the stomach antrum, it plays its role to control acidic secretions during digestion. Pathologic Condition hPG80 (circulating progastrin) is detected in the blood of cancer patients. When progastrin is not maturated into gastrin, it is released from the cells as such and named hPG 80 . ​ This only happens in tumor cells, whatever the tumor cell: progastrin becomes a circulating protein, hPG 80 , which can be detected in the blood of cancer patients. The ROCHE laboratory markets a test for the detection of Progastrin-releasing peptide (Pro-GRP) to differentiate between 2 types of lung cancer. hPG80 (Progastrin) and Progastrin-releasing peptide (Pro-GRP) are two completely different proteins even though they share the word "Progastrin / Pro-Gastrin” with the same phonetics. 2 hPG80 in cancer evolution The biomarker hPG 80 is present in the tumor / bloodstream of cancer patients at all stages of tumor progression, from primary tumor to metastasis. Example of CRC 3 Involvement of the Wnt pathway in tumorigenesis 3. 1 Activation – Non activation of Wnt/ß-Catenin Pathway The Wnt signaling pathway is an evolutionarily conserved signal transduction pathway that regulates a wide range of cellular functions during development and adulthood. It controls multiple aspects of development, including cell proliferation, cell fate determination, apoptosis, cell migration and cell polarity during development and stem cell maintenance in adults. Inappropriate activation of the Wnt pathway is also a major factor in human oncogenesis (Ng et al, Cells, 2019). Normal Cell: ON Normal Cell: OFF 3. 2 An early event in cancer development Chronic activation of the Wnt/ß-catenin pathway is a central mechanism in cancer biology that is implicated in: Induction of cellular proliferation and blocking of differentiation leading to primary tumor growth, Induction of epithelial mesenchymal transition (EMT) leading to metastasis formation, Regulation of cancer stem cell pathways leading to chemoresistance and relapse. 3. 3 hPG80: the gene coding for hPG80 is a direct Wnt/ß-catenin Target Gene GAST In normal cells: Tunable (On/Off) activation of the Wnt/ß-catenin target genes. In cancer cells: Constitutively activated Wnt/ß-catenin pathway leads to continuous expression of the gene coding for GAST hPG 80 and secretion of hPG 80 . Tumor Cell: always ON 4 hPG80, the biomarker of tumoral activity Cancer stem cells (CSCs) play an important role in tumor initiation and progression. ​ CSCs are cells within a tumor that possess the capacity to self-renew, to give rise to the heterogeneous lineages, to be resistant to standard therapy and to initiate tumor recurrence and metastasis (Curtin el al, Oncotarget 2010). ​ CSCs need hPG for their survival (Giraud et al, Cancer Research, 2016; Prieur et al, Clin Cancer Research, 2017). 80 ​ CSCs secrete 100 to 1000 more of hPG than non-CSC cancer cells (Prieur et al, Clin Cancer Research, 2017). 80 Secreted hPG maintains the stemness of CSCs (Prieur et al, Clin Cancer Research, 2017). 80 ​ Neutralization of secreted hPG by a therapeutic antibody decreases CSCs frequency, metastatic seeding, increases chemosensitivity and delays relapses (Prieur et al, Clin Cancer Research, 2017). 80 L earn more... about hPG 80 Performances

  • Home | ECS progastrin

    Last Update : Feb 02, 2020 News: Events Apr 21, 2020 1 min ASCO 2020 [May29 > Jun02] #ASCO20: We will present you the lastest results from work with our partners on the usefulness of targeting hPG80 for multiple cancers ! Apr 21, 2020 2 min A Major Publication: The Overexpression of hPG80 (circulating progastrin) in Multiple Cancers The technology we developed to detect hPG80 in the blood is robust, reliable and inexpensive, making this test easy to implement by onco... Apr 21, 2020 1 min Dr. Aman Chauhan MD (Markey Cancer Center) speaking about hPG80 at #GI ASCO 2020 HPG80 (Progastrin), a novel blood-based biomarker for detection of neuroendocrine neoplasms. GI ASCO / Presented Friday, January 24, 2020

  • hPH80 & Cancer | hPG80 for Colorectal Cancer | ECS Progastrin

    Contract signed with: Montpellier Cancer Institute, France ​ Principal investigator: Marc Ychou Quantification of hPG80 in the blood of patients with adenomatous and hyperplastic polyps and early stage colorectal cancer Last updated: August 3, 2020 1 Scientific context Liquid biopsy will become the new standard for diagnosing tumors and monitoring treatments (Bardelli et al, Cancer Cell, 2017). Plasma hPG 80 detection assay falls within this framework. ECS-Progastrin has developed a sandwich ELISA assay, which is reliable, simple, robust, inexpensive and used in almost all laboratories and hospitals around the world. ​ Using our ELISA assay, we have already demonstrated the presence of hPG 80 on a first cohort of colorectal cancer patients, mainly patients in late stages (more than 150 patients in stage 3 and 4) and some early stages (20 patients in stage 1 and 2). Whatever the stage, hPG 80 is detected with very good sensitivity. Similarly, we showed the presence of hPG 80 in the blood of 58 patients with adenomatous polyps, with very good sensitivity. With regard to hyperplastic polyps, we were only able to analyze the presence of hPG 80 in a limited number of cases (n = 10). hPG 80 was not detected in any of these patients. ​ This project aims to increase the number of patients with stage I and II colorectal cancer or with hyperplastic or adenomatous polyps, for whom we will measure plasma hPG 80 levels. This will clarify the value of hPG 80 as a biomarker for patients with early stages colorectal cancer and for patients with polyps. 2 hPG80, a new blood based biomarker Non Pathologic Condition hPG 80 is not found in the blood of healthy people. When progastrin is maturated into gastrin, it is released from the cells. ​ When gastrin is produced by the G cells of the stomach antrum, it plays its role to control acidic secretions during digestion. Pathologic Condition hPG 80 is detected in the blood of cancer patients. When progastrin is not maturated into gastrin, it is released from the cells as such and named hPG 80 . ​ This only happens in tumor cells, whatever the tumor cell: progastrin becomes a circulating protein, hPG 80 , which can be detected in the blood of cancer patients. 3 Objectives Show the presence or absence of hPG80 in the blood of patients with adenomatous polyps or with early colorectal cancer and establish the discriminative accuracy of hPG80 as a biomarker of these pathologies. ​ Correlate hPG80 levels with cancer stage. 4 Patients Cancer patients samples were obtained from SIRIC (Montpellier, FRANCE). Analyzes were performed within Eurobiodev facility (Montpellier, FRANCE). This retrospective study was approved by Montpellier cancer institute scientific council (ICM-CORT). Approval date and number: 13/11/2017 (ICM-CORT-2017-23) 96 patients were included in the study. Healthy blood donors samples were obtained from the French blood agency (EFS, Montpellier, FRANCE). Analyzes were performed within Eurobiodev facility (Montpellier, FRANCE). Approval date and number: 17/07/2017 (21PLER2017-0019) 80 non-fasting healthy donors were included in the study. 5 Results The presence of hPG80 in early colorectal cancer stages was confirmed. ​ Median hPG80 levels in CRC early stages patients were significantly higher than those in healthy blood donors (p< 0.0001) (Figure 1). Median hPG80 concentration was 0.23 pM (IQR 0.00-0.80 pM) in control population, against 2.315 pM (IQR 0.64-3.69 pM), 2.26 pM (IQR 0.70-9.60 pM), and 5.46 pM (IQR 1.67-9.945 pM) in patients with preneoplasic lesions, CRC stage 1 or CRC stage 2, respectively (Figure 1). There is a significant increase in hPG80 blood levels from adenomatous polyps to stage 2 colorectal cancer. Figure 1. Comparison of hPG80 concentrations between healthy blood donors (n=80) and cancers patients, preneoplasic lesions (n=24), stage 1 CRC (n=23), stage 2 CRC (n=49). Representation in box and Whiskers (2.5-97.5 percentile, dots are outliers). Two-tailed Mann-Whitney test; ***, p< 0.001; *, p< 0.05. The diagnostic discriminative accuracy of hPG80 levels was estimated using Receiver Operating Characteristics (ROC) curves in patients with preneoplasic lesions, patients with stage 1 CRC or patients with stage 2 CRC, compared to healthy blood donors control cohort. ​ The diagnostic discriminative accuracy estimated by the ROC AUC were 0.80 (95% CI: 0.69 to 0.91) for patients with preneoplasic lesions; 0.825 (95% CI: 0.72 to 0.93) for patients with stage 1 CRC; and 0.89 (95% CI: 0.82 to 0.95) for patients with stage 2 CRC, compared to the blood donor control group (Figures 2, 3 and 4). 6 Conclusion hPG80 is detected with a very good accuracy in the blood of patients with an adenomatous polyp or with a stage 1 or 2 colorectal cancer.

IT'S TIME TO CONTROL CANCER*

* IL EST TEMPS DE VAINCRE LE CANCER

Il a été démontré que la hPG80 (Progastrine circulante) est produite par toutes les cellules cancéreuses à tous les stades, mais en quantités 100 à 1000 fois plus élevées par les cellules souches cancéreuses considérées comme les principales responsables des récidives et des métastases.

 

La hPG80 est libérée de la tumeur et devient détectable dans le sang, faisant de la hPG80 le seul biomarqueur sanguin qui détecte non seulement la présence mais également l'activité de la tumeur.

 

16 cancers différents ont été testés, les 16 étaient positifs. Sur ces 16 cancers, 11 ont été publiés à ce jour.

 

La détection et le dosage de la hPG80 peuvent fournir aux médecins de nouvelles informations qui peuvent les aider dans :

  • L'évaluation de l'efficacité du traitement

  • L'évaluation du risque de récidives

  • L'évaluation du risque de maladie résiduelle minimale (MRD)

  • Le diagnostic des cancers sans biomarqueur et des populations à risque, afin de détecter suffisamment tôt la tumeur, facilement localisable dans ces populations.

ECS Progastrin est une filiale de Progastrine Invest SCSp (Fond de financement de la lutte contre le cancer)  11 côte d'Eich, L1450, Luxembourg - Grand-Duché du Luxembourg

PRINCIPALES IMPLANTATIONS  :

 

  • LUXEMBOURG

  • SUISSE

  • FRANCE

  • EMIRATS ARABES UNIS

  • ÉTATS UNIS D'AMÉRIQUE

PRINCIPALES ENTREPRISES :

  • ECS PROGASTRIN

  • ECS PROGASTRIN LAB

  • PROGASTRIN MANUFACTURING

  • PROGASTRINE ET CANCERS

  • EUROBIODEV

Progastrine Invest SCSp et ses filiales:

  • se concentrent sur l'innovation dans le diagnostic, la localisation, le suivi et le traitement du cancer,

  • détiennent les droits sur le premier test de détection et de dosage de hPG80 (Progastrine circulante) désormais disponible,

  • détiennent les droits sur le projet de thérapie contre le cancer avec un anticorps anti-hPG80.

 

Pour des raisons éthiques et par respect pour les praticiens, les établissements de santé, les populations et les réglementations en vigueur dans tous les pays où ils opèrent, Progastrine Invest SCSp et ses filiales accordent une extrême attention aux informations qu'ils fournissent publiquement.

 

La direction des filiales de Progastrine Invest SCSp et leur comité scientifique rappellent que seules les informations publiées sur les supports de communication officiels des sociétés du groupe peuvent être considérées comme confirmées et autorisées.

© 2015-2021 ECS-Progastrin ® - Tous droits réservés